Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk
4
FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera
5